» Articles » PMID: 23820258

Downregulation of MiR-302c and MiR-520c by 1,25(OH)2D3 Treatment Enhances the Susceptibility of Tumour Cells to Natural Killer Cell-mediated Cytotoxicity

Overview
Journal Br J Cancer
Specialty Oncology
Date 2013 Jul 4
PMID 23820258
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: NKG2D recognises several ligands, including polymorphic major histocompatibility complex class I chain-related chain-related proteins A and B (MICA/B) and unique long 16-binding proteins (ULBPs). These ligands are present on cancer cells and are recognised by NKG2D in a cell-structure-sensing manner, triggering natural killer (NK) cell cytotoxicity. However, the mechanisms that control the expression of NKG2D ligands in malignant cells are poorly understood. 1-α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) was recently shown to enhance the susceptibility of melanoma cells to the cytotoxicity of NK cells. However, the function of 1,25(OH)2D3 in other cancers and its potential mechanisms of action remain unknown.

Methods: The expression levels of miR-302c and miR-520c in Kasumi-1, K562, MCF7 and MDA-MB-231 cells were evaluated using quantitative real-time PCR. The targets of miR-302c and miR-520c were confirmed by luciferase reporter assay. The killing effects of NK92 cells against Kasumi-1, K562, MCF7 and MDA-MB-231 cells were examined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay. The levels of cytokines IFN-γ and granzyme B, which indicate the activation of NK cells, were also measured by enzyme-linked immunosorbent assay.

Results: Treatment with 1,25(OH)2D3 enhanced the susceptibility of both the haematological tumour cell line Kasumi-1 and solid tumour cell line MDA-MB-231 to NK92 cells. miR-302c and miR-520c expression was induced, and their levels inversely correlated with the levels of NKG2D ligands MICA/B and ULBP2 upon 1,25(OH)2D3 treatment. A luciferase reporter assay revealed that miR-302c and miR-520c directly targeted the 3'-UTRs of MICA/B and ULBP2 and negatively regulated the expression of MIA/B and ULBP2. Moreover, upregulation of miR-302c or miR-520c by transfection of their mimics remarkably reduced the viability of Kasumi-1 cells upon NK cell co-incubation. By contrast, the suppression of the activity of miR-302c or miR-520c by their respective antisense oligonucleotides improved the resistance of Kasumi-1 cells to NK cells.

Conclusion: 1,25(OH)2D3 facilitates the immuno-attack of NK cells against malignant cells partly through downregulation of miR-302c and miR-520c and hence upregulation of the NKG2D ligands MICA/B and ULBP2.

Citing Articles

The modulation of immune cell death in connection to microRNAs and natural products.

Chuang Y, Yen C, Tang J, Chang F, Tsai Y, Wu K Front Immunol. 2025; 15:1425602.

PMID: 39759512 PMC: 11695430. DOI: 10.3389/fimmu.2024.1425602.


Dietary Epigenetic Modulators: Unravelling the Still-Controversial Benefits of miRNAs in Nutrition and Disease.

Martino E, DOnofrio N, Balestrieri A, Colloca A, Anastasio C, Sardu C Nutrients. 2024; 16(1).

PMID: 38201989 PMC: 10780859. DOI: 10.3390/nu16010160.


Impact of MICA 3'UTR allelic variability on miRNA binding prediction, a bioinformatic approach.

Toledo-Stuardo K, Ribeiro C, Campos I, Tello S, Latorre Y, Altamirano C Front Genet. 2023; 14:1273296.

PMID: 38146340 PMC: 10749337. DOI: 10.3389/fgene.2023.1273296.


Expression study of microRNA cluster on chromosome 19 (C19MC) in tumor tissue and serum of breast cancer patient.

Altalebi S, Haghi M, Feizi M Mol Biol Rep. 2023; 50(12):9825-9831.

PMID: 37840066 DOI: 10.1007/s11033-023-08801-x.


Is there a rationale for supplementing with vitamin D patients under treatment with allergen immunotherapy?.

Di Gioacchino M, Petrarca C, Della Valle L, Mangifesta R, Santilli F Ann Med. 2023; 55(1):2230864.

PMID: 37387214 PMC: 10316735. DOI: 10.1080/07853890.2023.2230864.


References
1.
Trump D, Deeb K, Johnson C . Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010; 16(1):1-9. PMC: 2857702. DOI: 10.1097/PPO.0b013e3181c51ee6. View

2.
Chavez-Blanco A, De la Cruz-Hernandez E, Dominguez G, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E . Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011; 39(6):1491-9. DOI: 10.3892/ijo.2011.1144. View

3.
Obeidy P, Sharland A . NKG2D and its ligands. Int J Biochem Cell Biol. 2009; 41(12):2364-7. DOI: 10.1016/j.biocel.2009.07.005. View

4.
Vuolo L, Di Somma C, Faggiano A, Colao A . Vitamin D and cancer. Front Endocrinol (Lausanne). 2012; 3:58. PMC: 3355893. DOI: 10.3389/fendo.2012.00058. View

5.
Lee J, Park S, Cheon S, Lee J, Kim S, Hur D . 1,25-Dihydroxyvitamin D₃ enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur J Immunol. 2011; 41(10):2937-46. DOI: 10.1002/eji.201141597. View